Novavax AB is a biotechnology company based in Uppsala, Sweden. The company is primarily focused on the development of innovative vaccines to address various infectious diseases. Novavax utilizes its proprietary nanoparticle technology to create vaccine candidates that aim to elicit strong immune responses. This technology allows for the rapid development and production of vaccines, which is particularly relevant in responding to emerging health threats.
The company has been involved in several clinical trials to evaluate the safety and efficacy of its vaccine candidates. Novavax AB has gained attention for its work on vaccines for diseases such as influenza and COVID-19. The company collaborates with various public health organizations and research institutions to advance its vaccine development efforts and contribute to global health initiatives. Through these collaborations, Novavax aims to enhance its research capabilities and expand its impact in the field of biotechnology.